Better health is associated with a higher risk of heart disease.

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Better health is associated with a higher risk of heart disease.

Latest News

CMS Selects 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program

Icotrokinra Data at Maui Derm 2026 Reaffirm Efficacy in Psoriasis

Improving Recognition of Skin Disease in Diverse Skin Types, With Shawn Kwatra, MD, and Andrew Alexis, MD, MPH Shawn Kwatra, MD, Andrew F Alexis, MD, MPH

Practical Approaches to Hyperpigmentation and Hypopigmentation, With Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

Skin of Color Savvy: Highlights from 2025 Tim Smith

Skin of Color Savvy: On-Site Interviews at the Meeting the Challenge Summit Angel S. Byrd, MD, PhD, Valerie D. Callender, MD, Valerie Harvey, MD, MPH, Stafford Brown, MD, MBA

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Latest News

News All Time

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Digital Eczema Education Decreases Relapse Rates in Children in the Short-Term

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Pediatric Eczema Severity, Quality of Life Not Influenced by Phototype, Ethnicity

Upadacitinib Outperforms 4 JAK Inhibitors in Atopic Dermatitis Meta-Analysis

Dupilumab Most Effective Among Standard Drugs, Biologics in Prurigo Nodularis

Tralokinumab Consistently Effective for Eczema Regardless of Anatomical Site

Predictors Identified for Super-Responder Status to Dupilumab in Atopic Dermatitis

12 Months of Low-Level Laser Therapy at Home Improves Androgenetic Alopecia

BEACON: Positive Results Announced for Briquilimab in Chronic Spontaneous Urticaria

Family Quality of Life Burden in CSU Increased by Lack of Disease Control

Q4 2025 Recap: Dermatology News and Updates

Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis

Racial Disparities in Persistent Chemotherapy-Induced Alopecia Observed in Women

Dupilumab Effective for Children with Severe Atopic Dermatitis in Real World Setting

Recommended News For You

New study highlights success of financial toxicity tumor board in reducing cancer treatment costs

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

Studies point to redlining as a 'perfect storm' for breast cancer

Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill

high response rate when using a bispecific antibody to treat R/R multiple myeloma.

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

Recommended Articles For You

Exploring the Latest Advances in PTLD Cancer Treatment

Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology

Everything You Need to Know About RDW-CV: A Comprehensive Guide

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.